Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical trial of INZ-701 in children with ABCC6 Deficiency.

X
Trial Profile

Clinical trial of INZ-701 in children with ABCC6 Deficiency.

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INZ-701 (Primary)
  • Indications Calcinosis
  • Focus Adverse reactions
  • Sponsors Inozyme Pharma
  • Most Recent Events

    • 16 Jan 2025 New trial record
    • 10 Jan 2025 According to Inozyme Pharma media relase, the company plans to initiate the ASPIRE trial in early 2026.
    • 10 Jan 2025 According to Inozyme Pharma media relase, Inozyme is currently refining the study design to harmonize feedback from the FDA and EMA.Also The Company plans to continue regulatory engagement over the coming months to finalize the trial protocol. Pending ongoing regulatory review and the availability of financial resources.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top